Case Study

The miracle balm of Gilead (B)

6 pages
April 2015
Reference: IMD-7-1620

The second part of this case series describes the protests about the cost of Sovaldi which continued throughout the summer of 2014, not only in emerging markets but also in developed countries. In PR terms, Gilead was being painted less as a marvelous creator of a miracle drug and more as an arbiter of who might live or die from hepatitis C, based entirely on whether they could afford it or not. In September 2014, Gilead surprised everyone.

Biotechnology, Health Care, Health Care Costs, Health Insurance, Pricing, Non-Governmental Organization, Pressure Group, Competitor Analysis, Epidemiology, Medecine
Global, United States of America
Gilead Sciences, Manufacturing, Biotechnology, Healthcare, Pharmaceuticals
Published Sources
© 2015
Available Languages
Case clearing houses
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]


Research Information & Knowledge Hub for additional information on IMD publications

Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics